- Home
- CFND vs ALGS Comparison
CFND vs ALGS Comparison
Compare CFND & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFND | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 57.2M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CFND | ALGS |
|---|---|---|
| Price | $5.10 | $11.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | N/A | ★ 73.7K |
| Earning Date | N/A | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $3.76 |
| 52 Week High | N/A | $46.80 |
Technical Indicators
Market Signals| Indicator | CFND | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 70.56 |
| Support Level | N/A | $9.10 |
| Resistance Level | N/A | $10.45 |
| Average True Range (ATR) | 0.00 | 0.66 |
| MACD | 0.00 | 0.28 |
| Stochastic Oscillator | 0.00 | 97.16 |
Price Performance
Historical ComparisonAbout CFND C1 Fund Inc.
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.